Holiday Notification: Cayman Chemical will be closed Monday, May 28, 2012, in observance of the Memorial Day holiday.
More…
Please feel free to continue placing orders via our website or via fax at 734-971-3640. You may send an email to customer service at custserv@caymanchem.com , or to technical support at techserv@caymanchem.com which we will respond to the next business day. Cayman will resume regular business hours and shipping schedules on Tuesday, May 29, 2012. Thank you for your patience and understanding.
Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase is the rate-limiting enzyme in the cholesterol biosynthetic pathway and the target of the “statin” class of cholesterol-lowering drugs.1 Lovastatin is an HMG-CoA reductase inhibitor that was initially isolated from Aspergillus terreus.2 Marketed as Mevinolin™, Mevacor™, and under several other trade names, Lovastatin was the first HMG-CoA reductase inhibitor to be used in the treatment of hypercholesterolemia. It is a competitive inhibitor of HMG-CoA reductase with a Ki value of 0.6 nM for the open ring, hydroxy acid form of the molecule.3 During a three week study in dogs, a dose of 8 mg/kg per day resulted in a 29% reduction in plasma cholesterol.3 Lovastatin also suppresses TNF-induced NF-κB activation (IC50 ~ 15 µM), which potentiates apoptosis in human myeloid leukemia cells and thus, maybe useful in treating cancer.4
1
Tobert, J.A. Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov2517-526(2003).
2
Endo, A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res331569-1582(1992).
3
Alberts, A.W., Chen, J., Kuron, G., et al. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA77(7)3957-3961(1980).
4
Ahn, K.S., Sethi, G., and Aggarwal, B.B. Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-κB pathway. Biochem Pharmacol75907-913(2008).
Tobert, J.A. Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov2517-526(2003).
Endo, A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res331569-1582(1992).
Ahn, K.S., Sethi, G., and Aggarwal, B.B. Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-κB pathway. Biochem Pharmacol75907-913(2008).
Alberts, A.W., Chen, J., Kuron, G., et al. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA77(7)3957-3961(1980).